Attached files

file filename
8-K - 8-K - MAGELLAN HEALTH INCa13-17177_18k.htm

Exhibit 99.1

 

GRAPHIC

NEWS RELEASE

Media Contact: David Carter, dwcarter@magellanhealth.com, (860) 507-1909
Investor Contact: Renie Shapiro, rshapiro@magellanhealth.com, (877) 645-6464

 

MAGELLAN HEALTH SERVICES REPORTS

SECOND QUARTER 2013 FINANCIAL RESULTS

 

- Board of Directors Extends and Increases Share Repurchase Program -

 

AVON, Conn. – July 25, 2013 – Magellan Health Services Inc. (NASDAQ: MGLN) today reported financial results for the second quarter 2013, as summarized below. For the quarter ended June 30, 2013, the company reported net revenue of $842.7 million, segment profit of $75.0 million, and net income of $31.5 million or $1.15 per diluted common share. Segment profit represents income from operations before stock compensation expense, depreciation and amortization, interest expense, interest income, gain on sale of assets, special charges or benefits and income taxes.

 

Financial Results

 

 

 

Three Months Ended June 30, 2013

 

Six Months Ended June 30, 2013

 

(Millions, except per share results)

 

2013

 

2012

 

Increase/
(Decrease)

 

2013

 

2012

 

Increase/
(Decrease)

 

Revenue

 

$

842.7

 

$

805.5

 

4.6

%

$

1,664.5

 

$

1,578.7

 

5.4

%

Segment Profit

 

75.0

 

64.8

 

15.7

%

144.3

 

120.2

 

20.0

%

Net Income

 

31.5

 

27.0

 

16.7

%

59.5

 

47.8

 

24.5

%

Earnings Per Share

 

1.15

 

0.97

 

18.6

%

2.17

 

1.72

 

26.2

%

 

As of June 30, 2013, the company had unrestricted cash and investments of $281.9 million.

 

“I am pleased with Magellan’s strong second quarter performance and the strides we made in our growth initiatives,” said Barry M. Smith, chief executive officer. “This is a time of transformation at Magellan, as we build on the solid foundation developed over the past several years and evolve into a business with a sharp focus on leveraging our unique strengths, particularly with regard to managing special populations. We have developed our Magellan Complete Care and Magellan Pharmacy Solutions initiatives to address opportunities that we see in the marketplace and to be our primary growth engines for the future.

 

“Our core behavioral health, radiology and pharmacy businesses continue to perform well and are making significant contributions to our results. They have fueled our past growth and, going forward, will provide the clinical capabilities to holistically manage enrollees in our Magellan Complete Care programs. For example, our new health plan, Magellan Complete Care of Florida, which began enrolling members during the quarter, leverages the assets of our entire product portfolio. We are moving decisively to simplify and retool our offerings, sharpen our business focus and position the company for continued growth.”

 



 

Share Repurchase Program

 

The Board of Directors has approved a $100 million increase to the current $200 million share repurchase authorization and extended it for two years until October 25, 2015. The shares may be purchased from time to time on the open market, under 10b5-1 plans, or in privately negotiated transactions. There are a number of factors that affect the timing and pace of purchases, such as stock price, projected capital needs, M&A prospects and determination of open and closed trading windows.

 

Outlook

 

“We had strong results this quarter and are maintaining our full-year outlook for revenue, net income, segment profit and EPS,” said Jonathan N. Rubin, chief financial officer. “The increased share repurchase authorization reflects our Board of Directors’ confidence in our growth strategy, cash flow and financial capacity. We are committed to maximizing long-term shareholder value through both share repurchases and continued investment in our growth initiatives.”

 

Earnings Results Conference Call

 

Management will host a conference call at 10:00 a.m. Eastern Time on Thursday, July 25, 2013. To participate in the conference call, interested parties should call 1-800-857-1812 and reference the pass code Second Quarter Earnings Call 2013 approximately 15 minutes before the start of the call. The conference call will also be available via a live Webcast at Magellan’s investor relations page at www.MagellanHealth.com.

 

About Magellan Health Services: Headquartered in Avon, Conn., Magellan Health Services Inc. is a leading specialty health care management organization with expertise in managing behavioral health, radiology, and pharmacy benefits programs, as well as integrated health care programs for special populations. Magellan delivers innovative solutions to improve quality outcomes and optimize the cost of care for those we serve. As of June 30, 2013, Magellan’s customers include health plans, employers and government agencies, serving approximately 34.0 million members in our behavioral health business, 17.4 million members in our radiology benefits management segment, and approximately 9 million members in our medical pharmacy management product. In addition, the pharmacy solutions segment served 40 health plans and employers, 25 states and the District of Columbia, and several pharmaceutical manufacturers. For more information, visit www.MagellanHealth.com.

 

Cautionary Statement

 

This release contains forward-looking statements within the meaning of the Securities Exchange Act of 1934 and the Securities Act of 1933, as amended, which involve a number of risks and uncertainties. All statements, other than statements of historical information provided herein, may be deemed to be forward-looking statements including, without limitation, statements regarding estimates of 2013 revenue, net income, segment profit, earnings per share, strategy and growth. These statements are based on management’s analysis, judgment, belief and expectation only as of the date hereof, and are subject to uncertainty and changes in circumstances. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “may,” “should,” “could,” “estimate,” “intend” and other similar expressions are intended to identify forward-looking statements. Actual results could differ materially due to, among other things, the possible election of certain of the company’s customers to manage the health care services of their members directly; changes in rates paid to and/or by the company by customers and/or providers; higher utilization of health care services by the company’s risk members; delays, higher costs or inability to implement new business or other company initiatives; the impact of changes in

 



 

the contracting model for Medicaid contracts; termination or non-renewal of customer contracts; the impact of new or amended laws or regulations; governmental inquiries; litigation; competition; operational issues; health care reform; and general business conditions. Additional factors that could cause actual results to differ materially from those reflected in the forward-looking statements include, but are not limited to, the risks discussed in the “Risk Factors” section included within the company’s Annual Report on Form 10-K for the year ended December 31, 2012, filed with the Securities and Exchange Commission on February 28, 2013, and the company’s subsequent Quarterly Reports on Form 10-Q filed during 2013. Readers are cautioned not to place undue reliance on these forward-looking statements. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date of this release. Segment profit information referred to herein may be considered a non-GAAP financial measure. Further information regarding this measure, including the reasons management considers this information useful to investors, are included in the company’s most recent Annual Report on Form 10-K and on subsequent Form 10-Qs.

 

Media Contact

David W. Carter

860-507-1909

DWCarter@MagellanHealth.com

 

Investor Contact

Renie Shapiro

877-645-6464

RShapiro@MagellanHealth.com

 

# # #

 



 

MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(Unaudited)

(In thousands, except per share amounts)

 

 

 

Three Months Ended June 30,

 

Six months Ended June 30,

 

 

 

2012

 

2013 (1)

 

2012

 

2013 (1)

 

 

 

 

 

 

 

 

 

 

 

Net revenue:

 

 

 

 

 

 

 

 

 

Managed care and other

 

$

716,998

 

$

752,151

 

$

1,403,057

 

$

1,479,791

 

Dispensing

 

88,475

 

90,597

 

175,629

 

184,718

 

Total net revenue

 

805,473

 

842,748

 

1,578,686

 

1,664,509

 

 

 

 

 

 

 

 

 

 

 

Cost and expenses:

 

 

 

 

 

 

 

 

 

Cost of care

 

521,830

 

542,826

 

1,027,123

 

1,072,757

 

Cost of goods sold

 

82,855

 

84,979

 

163,893

 

173,587

 

Direct service costs and other operating expenses (2) 

 

140,333

 

144,497

 

276,922

 

284,124

 

Depreciation and amortization

 

15,152

 

16,946

 

29,933

 

33,116

 

Interest expense

 

576

 

792

 

1,176

 

1,402

 

Interest income

 

(857

)

(358

)

(1,269

)

(711

)

 

 

759,889

 

789,682

 

1,497,778

 

1,564,275

 

Income before income taxes

 

45,584

 

53,066

 

80,908

 

100,234

 

Provision for income taxes

 

18,611

 

21,586

 

33,145

 

40,696

 

Net income

 

26,973

 

31,480

 

47,763

 

59,538

 

Other comprehensive (loss) income (3) 

 

(85

)

(70

)

88

 

(147

)

Comprehensive income

 

$

26,888

 

$

31,410

 

$

47,851

 

$

59,391

 

 

 

 

 

 

 

 

 

 

 

Weighted average number of common shares outstanding — basic

 

27,317

 

26,829

 

27,258

 

26,968

 

Weighted average number of common shares outstanding — diluted

 

27,717

 

27,338

 

27,732

 

27,492

 

 

 

 

 

 

 

 

 

 

 

Net income per common share — basic

 

$

0.99

 

$

1.17

 

$

1.75

 

$

2.21

 

Net income per common share — diluted

 

$

0.97

 

$

1.15

 

$

1.72

 

$

2.17

 

 


(1) For a more detailed discussion of Magellan’s results for the quarterly period ended June 30, 2013, refer to the Company’s Quarterly Report on Form 10-Q, which will be filed with the SEC on Thursday, July 25, 2013, and the live broadcast or taped replay of the Company’s earnings conference call on Thursday, July 25, 2013, which will be available at www.MagellanHealth.com.

 

(2) Includes stock compensation expense of $4,365 and $4,602 for the three months ended June 30, 2012 and 2013, respectively, and $9,467 and $10,240 for the six months ended June 30, 2012 and 2013, respectively.

 

(3) Net of income tax provision (benefit) of $(55) and $(47) for the three months ended June 30, 2012 and 2013, respectively, and and $56 and $(99) for the six months ended June 30, 2012 and 2013, respectively.

 



 

MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)

 

 

 

Six Months Ended June 30,

 

 

 

2012

 

2013 (1)

 

 

 

 

 

 

 

Cash flows from operating activities:

 

 

 

 

 

Net income

 

$

47,763

 

$

59,538

 

 

 

 

 

 

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

 

Depreciation and amortization

 

29,933

 

33,116

 

Non-cash interest expense

 

360

 

368

 

Non-cash stock compensation expense

 

9,467

 

10,240

 

Non-cash income tax expense

 

6,906

 

1,335

 

Non-cash amortization on investments

 

3,720

 

4,884

 

Cash flows from changes in assets and liabilities, net of effects from acquisitions of businesses:

 

 

 

 

 

Restricted cash (2) 

 

(22,845

)

37,086

 

Accounts receivable, net

 

1,428

 

(27,361

)

Pharmaceutical inventory

 

1,213

 

(4,150

)

Other assets

 

(4,307

)

(8,281

)

Accounts payable and accrued liabilities

 

(20,022

)

(29,643

)

Medical claims payable and other medical liabilities

 

20,208

 

6,384

 

Tax contingencies

 

1,478

 

1,349

 

Other

 

(270

)

2,044

 

Net cash provided by operating activities

 

75,032

 

86,909

 

 

 

 

 

 

 

Cash flows from investing activities:

 

 

 

 

 

Capital expenditures

 

(36,877

)

(27,035

)

Purchase of investments

 

(143,155

)

(165,372

)

Maturity of investments

 

150,890

 

139,068

 

Other

 

 

(7,900

)

Net cash used in investing activities

 

(29,142

)

(61,239

)

 

 

 

 

 

 

Cash flows from financing activities:

 

 

 

 

 

Payments to acquire treasury stock

 

 

(49,462

)

Proceeds from exercise of stock options and warrants

 

3,003

 

16,110

 

Payments on capital lease obligations

 

 

(1,816

)

Other

 

(735

)

(747

)

Net cash provided by (used in) financing activities

 

2,268

 

(35,915

)

 

 

 

 

 

 

Net increase (decrease) in cash and cash equivalents

 

48,158

 

(10,245

)

Cash and cash equivalents at beginning of period

 

119,862

 

189,464

 

Cash and cash equivalents at end of period

 

$

168,020

 

$

179,219

 

 


(1) The Company’s Quarterly Report on Form 10-Q for the six months ended June 30, 2013 will be filed with the SEC on Thursday, July 25, 2013.

 

(2)  Includes the net shift of restricted funds between cash and investments that results in an operating cash flow change that is directly offset by an investing cash flow change.  During the six months ended June 30, 2012, restricted investments of $19,474 were shifted to restricted cash that resulted in an operating cash flow use, with restricted cash of $31,249 shifted to restricted investments during the six months ended June 30, 2013 that resulted in an operating cash flow source.

 



 

MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

CONSOLIDATED OPERATING RESULTS BY BUSINESS SEGMENT

(Unaudited)

(In thousands)

 

 

 

Three Months Ended June 30,

 

Six Months Ended June 30,

 

 

 

2012

 

2013 (1)

 

2012

 

2013 (1)

 

 

 

 

 

 

 

 

 

 

 

Managed care and other revenue

 

 

 

 

 

 

 

 

 

- Commercial

 

$

178,227

 

$

199,538

 

$

358,751

 

$

387,375

 

- Public Sector

 

410,136

 

414,859

 

799,024

 

821,479

 

- Radiology Benefits Management

 

88,826

 

92,715

 

165,683

 

182,993

 

- Pharmacy Solutions (2)

 

56,527

 

61,260

 

117,425

 

119,410

 

- Elimination (2) 

 

(16,718

)

(16,221

)

(37,826

)

(31,466

)

Total managed care and other revenue

 

716,998

 

752,151

 

1,403,057

 

1,479,791

 

 

 

 

 

 

 

 

 

 

 

Dispensing revenue - Pharmacy Solutions

 

88,475

 

90,597

 

175,629

 

184,718

 

 

 

 

 

 

 

 

 

 

 

Cost of care

 

 

 

 

 

 

 

 

 

- Commercial

 

110,847

 

123,227

 

223,019

 

236,498

 

- Public Sector (2) 

 

355,113

 

357,402

 

699,425

 

712,781

 

- Radiology Benefits Management

 

57,874

 

58,742

 

108,284

 

116,809

 

- Pharmacy Solutions

 

14,714

 

19,676

 

34,221

 

38,135

 

- Elimination (2) 

 

(16,718

)

(16,221

)

(37,826

)

(31,466

)

Total cost of care

 

521,830

 

542,826

 

1,027,123

 

1,072,757

 

 

 

 

 

 

 

 

 

 

 

Cost of goods sold - Pharmacy Solutions

 

82,855

 

84,979

 

163,893

 

173,587

 

 

 

 

 

 

 

 

 

 

 

Direct service costs and other operating expenses

 

 

 

 

 

 

 

 

 

- Commercial

 

42,456

 

41,399

 

84,818

 

82,791

 

- Public Sector

 

23,304

 

28,934

 

43,901

 

54,577

 

- Radiology Benefits Management

 

13,582

 

13,863

 

27,068

 

27,234

 

- Pharmacy Solutions

 

26,948

 

31,374

 

55,967

 

60,935

 

- Corporate

 

34,043

 

28,927

 

65,168

 

58,587

 

Total direct service costs and other operating expenses

 

140,333

 

144,497

 

276,922

 

284,124

 

 

 

 

 

 

 

 

 

 

 

Stock compensation expense (3)

 

 

 

 

 

 

 

 

 

- Commercial

 

(270

)

(133

)

(537

)

(266

)

- Public Sector

 

(269

)

(267

)

(556

)

(574

)

- Radiology Benefits Management

 

(360

)

(457

)

(760

)

(891

)

- Pharmacy Solutions

 

(236

)

(380

)

(466

)

(700

)

- Corporate

 

(3,230

)

(3,365

)

(7,148

)

(7,809

)

Total stock compensation expense

 

(4,365

)

(4,602

)

(9,467

)

(10,240

)

 

 

 

 

 

 

 

 

 

 

Segment profit (loss)

 

 

 

 

 

 

 

 

 

- Commercial

 

25,194

 

35,045

 

51,451

 

68,352

 

- Public Sector

 

31,988

 

28,790

 

56,254

 

54,695

 

- Radiology Benefits Management

 

17,730

 

20,567

 

31,091

 

39,841

 

- Pharmacy Solutions

 

20,721

 

16,208

 

39,439

 

32,171

 

- Corporate and Elimination

 

(30,813

)

(25,562

)

(58,020

)

(50,778

)

Total segment profit

 

$

64,820

 

$

75,048

 

$

120,215

 

$

144,281

 

 

 

 

 

 

 

 

 

 

 

Reconciliation of segment profit to income before income taxes:

 

 

 

 

 

 

 

 

 

Segment profit

 

$

64,820

 

$

75,048

 

$

120,215

 

$

144,281

 

Stock compensation expense

 

(4,365

)

(4,602

)

(9,467

)

(10,240

)

Depreciation and amortization

 

(15,152

)

(16,946

)

(29,933

)

(33,116

)

Interest expense

 

(576

)

(792

)

(1,176

)

(1,402

)

Interest income

 

857

 

358

 

1,269

 

711

 

Income before income taxes

 

$

45,584

 

$

53,066

 

$

80,908

 

$

100,234

 

 


(1) The Company’s Quarterly Report on Form 10-Q for the six months ended June 30, 2013 will be filed with the SEC on Thursday, July 25, 2013.

 

(2) Public Sector has subcontracted with Pharmacy Solutions to provide pharmacy benefits management services on a limited risk basis for one of Public Sector’s customers.  As such, revenue and cost of care related to this intersegment arrangement are eliminated.

 

(3) Stock compensation expense is included in direct service costs and other operating expenses; however, this amount is excluded from the computation of segment profit since it is managed on a consolidated basis.